Is CC a Buy or a Sell? The Bull and Bear Case (2026)

Last updated July 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for The Chemours Company (CC) rests on Opteon refrigerant growth: The Thermal & Specialized Solutions segment, anchored by Opteon low-GWP refrigerants, is Chemours' clearest growth engine. The bear case rests on pFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the $450 million EPA and DOJ settlement already reached in 2026. Analysts covering it publish targets from $19.00 to $30.00 against a $16.42 price, so even the professionals disagree by 45% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

The Chemours Company is a US-listed specialty chemicals producer spun out of DuPont in 2015. It reports through three segments: Thermal & Specialized Solutions (refrigerants and thermal management, led by the Opteon low-global-warming-potential product line), Titanium Technologies (TiO2 white pigment used in paints, plastics, and paper), and Advanced Performance Materials (high-end fluoropolymers and advanced materials). Full-year 2025 net sales were roughly $5.8 billion, and the company operates globally across industrial, construction, automotive, and electronics end markets. The investment picture is a barbell. Opteon refrigerants are benefiting from the regulatory phase-down of higher-emission HFCs under the AIM Act, giving Chemours a structurally growing, higher-margin franchise. Against that, the Titanium Technologies business is deeply cyclical and has faced soft pricing and demand tied to construction and coatings, while the company carries substantial, widely reported PFAS environmental and litigation liabilities. Chemours reached a $450 million EPA and DOJ settlement in June 2026 covering several legacy facilities, but AFFF multi-district litigation and other claims remain unresolved, keeping the balance sheet and legal exposure central to how the stock trades.

The bull case: what would have to be true for $30.00

The most optimistic published target on CC is $30.00, +82.7% from the $16.42 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Opteon refrigerant growth

The Thermal & Specialized Solutions segment, anchored by Opteon low-GWP refrigerants, is Chemours' clearest growth engine. Regulatory HFC phase-downs under the AIM Act and similar rules abroad are shifting demand toward the newer chemistries Chemours produces. Management has pointed to this franchise as the main driver behind its 2026 guidance for net sales growth of roughly 3 to 5 percent.

2. TiO2 pigment cyclical recovery

Titanium Technologies is the largest revenue segment and is highly sensitive to construction, coatings, and industrial demand. Pricing and volumes have been pressured through the recent cycle, so any recovery in global coatings demand or pigment pricing would be a meaningful earnings lever. The flip side is that continued weakness keeps consolidated margins subdued.

3. Cost, cash flow, and dividend

Chemours has emphasized cost discipline, capital-expenditure control (guided to roughly $275 to $325 million in 2026), and free cash flow conversion above 20 percent. The company pays a modest dividend of about $0.35 per share annually. Delivering on its $800 to $900 million adjusted EBITDA guidance would support the balance sheet and its litigation obligations.

4. PFAS liability resolution

Progress on resolving PFAS exposure is itself a potential catalyst. The June 2026 EPA and DOJ settlement of about $450 million removed some uncertainty at legacy sites. Further settlements or favorable outcomes in the remaining AFFF litigation could reduce the discount the market applies, though the timing and size of remaining liabilities are uncertain.

The bear case: what would have to be true for $19.00

The most pessimistic published target is $19.00, +15.7% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks The Chemours Company is worth if the risks below bite instead of the drivers above.

PFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the $450 million EPA and DOJ settlement already reached in 2026. The Titanium Technologies segment is cyclical and exposed to weak construction and coatings demand plus low-cost pigment competition. The company posted a net loss in Q1 2026, underscoring thin profitability. Leverage and the cash demands of legal settlements constrain financial flexibility. Regulatory, raw-material, and currency swings add further volatility to results.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding CC already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on CC

9 analysts cover CC, with an average target of $24.67 (+50.2% against $16.42) and a split of 5 buy, 4 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the CC forecast and price target page.

How is CC valued? (as of JULY 2026)

Price

$16.42

Market cap

$2.47B

Forward P/E

7.36

Price / book

11.48

Beta

1.40

52-week range

$10.44 to $28.67

Snapshot for CC as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (FY2025): ~$5.8B
Q1 2026 revenue: ~$1.38B
Q1 2026 net loss: ~$29M
2026 adj. EBITDA guide: ~$800-900M
Market cap: ~$3.3B
Dividend yield: ~1.5%

Chemours trades at a low equity valuation relative to its ~$5.8 billion revenue base, reflecting cyclical earnings and PFAS liability overhang rather than a high-growth multiple. Q1 2026 showed revenue up modestly year over year but a net loss, with 2026 guidance calling for 3 to 5 percent sales growth. EV/EBITDA has run in the low-to-mid teens, so much of the enterprise value sits in debt and litigation obligations.

How do you decide if CC is a buy?

Rather than asking whether CC is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold CC indirectly through an index or sector ETF before adding more.

What would change your mind on CC

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: Opteon refrigerant growth stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: pFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the $450 million EPA and DOJ settlement already reached in 2026 fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the CC stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CC against your real portfolio and see your actual exposure before deciding.

Investing in The Chemours Company with AI

Connect the broker you already use and ask Walnut's AI how CC fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Create a free Walnut account

FAQ

Is CC a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on Opteon refrigerant growth, with revenue (fy2025) at ~$5.8B. The bear case rests on pFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the $450 million EPA and DOJ settlement already reached in 2026. Analysts covering it are spread from $19.00 to $30.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell CC?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. PFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the $450 million EPA and DOJ settlement already reached in 2026. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $19.00, +15.7% from the $16.42 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for CC?

Opteon refrigerant growth. The Thermal & Specialized Solutions segment, anchored by Opteon low-GWP refrigerants, is Chemours' clearest growth engine. The most optimistic analyst target on CC is $30.00, +82.7% from the $16.42 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for CC?

What does The Chemours Company do?

The Chemours Company is a US-listed specialty chemicals producer spun out of DuPont in 2015.

What would have to change for CC to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Opteon refrigerant growth) stalling in the reported numbers rather than in the narrative, the risk above (pFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the $450 million EPA and DOJ settlement already reached in 2026) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Chemours do?

Chemours is a US specialty chemicals company that makes TiO2 white pigment, Opteon low-global-warming-potential refrigerants, and advanced fluoropolymers. It was spun out of DuPont in 2015 and sells into coatings, plastics, refrigeration, automotive, and industrial markets worldwide.

What are Chemours' business segments?

The company reports three segments: Thermal & Specialized Solutions (refrigerants and thermal management), Titanium Technologies (TiO2 pigment), and Advanced Performance Materials (fluoropolymers and advanced materials), plus a smaller Performance Chemicals and Intermediates business.

How much revenue does Chemours generate?

Chemours reported full-year 2025 net sales of roughly $5.8 billion, about flat versus the prior year. First-quarter 2026 revenue was around $1.38 billion, up modestly year over year, though the quarter carried a net loss of about $29 million.

Walnut is informational, not investment advice, and gives no verdict on CC. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.